2-(1-piperazinyl)-4H-pyrido<1,2-a>pyrimidin-4-one | 168425-51-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(1-piperazinyl)-4H-pyrido<1,2-a>pyrimidin-4-one
• 英文别名: 2-Piperazin-1-ylpyrido[1,2-a]pyrimidin-4-one
• CAS: 168425-51-2
• 化学式: C₁₂H₁₄N₄O
• 分子量: 230.269
• InChiKey: YMZVMQZXOZLAIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(1-piperazinyl)-4H-pyrido<1,2-a>pyrimidin-4-one 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、206.84 kPa 条件下， 反应 3.0h， 以44%的产率得到2-Piperazin-1-yl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one
  参考文献：
  名称：

  Synthesis, antiplatelet activity and comparative molecular field analysis of substituted 2-amino-4 H -pyrido[1,2- a ]pyrimidin-4-ones, their congeners and isosteric analogues

  摘要：

  2-(1-Piperazinyl)-4H-pyrido[1,2-a]pyrimidin-4-one (5a) is a recently described in vitro inhibitor of human platelet aggregation which specifically inhibits the activity of high affinity cAMP phosphodiesterase. A number of substitution derivatives, isosteres, and analogues of 5a were now synthesized and tested in vitro for their inhibitory activity on human platelet aggregation induced in platelet-rich plasma by ADP, collagen, or the Ca2+ ionophore A23187. Among the most effective compounds, the 6-methyl, 8-methyl and 6,8-dimethyl derivatives of 5a resulted nearly as active as the lead when platelet aggregation was induced by ADP or A23187, but less active when collagen was the inducer. On the basis of present results and those previously obtained by us in this and 2-aminochromone structural fields, we have developed a statistically significant 3-D QSAR model, using comparative molecular field analysis (CoMFA), describing the variation of the antiplatelet activity in terms of molecular steric and electrostatic potential changes. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00010-9
• 作为产物：
  描述：

  哌嗪 、 2-氯-4H-吡啶并[1,2-a]嘧啶-4-酮 以 乙醇 为溶剂， 反应 2.0h， 以88%的产率得到2-(1-piperazinyl)-4H-pyrido<1,2-a>pyrimidin-4-one
  参考文献：
  名称：

  1,2-Fused pyrimidines VII. 3-(Dialkylamino)-1H-pyrimido[1,2-a]quinolin-1-ones and 2-(dialkylamino)-4H-pyrimido[2,1-a]isoquinolin-4-ones as antiplatelet compounds

  摘要：

  A number of 3-(dialkylamino)-1H-pyrimido[1,2-a]quinolin-1 ones 3 and 2-(dialkylamino)-4H-pyrimido [2,1-a]isoquinolin-4-ones 4 were prepared by treating the corresponding chloro derivatives with an excess of dialkylamines. The highest in vitro antiplatelet activity was obtained when the dialkylamino substituent was 1-piperazinyl (compounds 3g and 4e). The novel 2-(1-piperazinyl)-4H-pyrido[ ,2-a]pyrimidin-4-one 2a was also prepared by an analogous procedure, which resulted in the most active compound towards all the platelet aggregation inducers used (ADP, collagen, A 23187). Moreover, some examples of 1-(dialkylamino)-3H pyrimido[l,2-a]quinolin-3-ones 5 and 4-(dialkylamino)-2H-pyrimido[2,1-a]isoquinolin-2-ones 6 were also obtained (together with negligible or lower amounts of the corresponding isomers 3 and 4, respectively) from the cyclocondensation of the appropriate ethyl N,N-dialkylmalonamate/phosphorus oxychloride reagents 13 with 2-aminoquinoline or 1-aminoisoquinoline. These;latter compounds showed a rather low antiplatelet activity.

  DOI：

  10.1016/0223-5234(96)88206-7

文献信息

• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics, Inc.

  公开号：US20180105526A1

  公开（公告）日：2018-04-19

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组成物和使用方法。
• Compounds for treating spinal muscular atrophy
  申请人：PTC Therapeutics, Inc.

  公开号：US10851101B2

  公开（公告）日：2020-12-01

  Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.

  本文提供的是式 (I) 化合物： 及其形式，包括其组合物和用途，用于治疗脊髓性肌萎缩症。
• SCREENING METHOD
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3035935A2

  公开（公告）日：2016-06-29
• METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY
  申请人：Whalen Anne

  公开号：US20110224128A1

  公开（公告）日：2011-09-15

  The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.
• US9586955B2
  申请人：——

  公开号：US9586955B2

  公开（公告）日：2017-03-07